Sign up to save your podcasts
Or
Share Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
View all episodes
By cancerGRACE - H. Jack West, MD
5
11 ratings
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
More shows like GRACEcast Lung Cancer Video
View all
GRACEcast Head and Neck Cancer Audio
2 Listeners
GRACEcast Radiation Oncology Audio
0 Listeners
GRACEcast Radiation Oncology Video
0 Listeners
GRACEcast Pancreatic Cancer Audio
0 Listeners
GRACEcast Pancreatic Cancer Video
1 Listeners
GRACEcast Cancer 101 Audio
0 Listeners
GRACEcast Bladder Cancer Video
0 Listeners
GRACEcast Head and Neck Cancer Video NEW
0 Listeners
GRACEcast Cancer 101 Video
0 Listeners